Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon

#MindfulMondays with Miss SA

teen suicide icon


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue1

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

News Author: Yael Waknine
CME Author: Yael Waknine
Complete author affiliations and disclosures, and other CME information, are available at the end of this activity.Release Date: June 15, 2006; Valid for credit through June 15, 2007

Credits Available

Physicians - up to 0.25 AMA PRA Category 1 Credit(s)™ for physicians ;
Family Physicians - up to 0.25 AAFP Prescribed credit(s) for physicians ;
Nurses - 0.3 ANCC continuing education contact hours for nurses (0.3 contact hours are in the area of pharmacology)
All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.
Participants should claim only the number of hours actually spent in completing the educational activity.

June 15, 2006 — The US Food and Drug Administration (FDA) has approved a new indication for bupropion HCl extended-release tablets, allowing their use for the prevention of major depressive episodes in patients with a history of seasonal affective disorder; and 5-mg/40-mg and 10-mg/40-mg formulations of amlodipine besylate/benazepril HCl capsules for the treatment of uncontrolled hypertension.

Bupropion Extended-Release Tablets (Wellbutrin XL) Approved for SAD

On June 12, the FDA approved a new indication for bupropion HCl extended-release tablets (Wellbutrin XL, made by GlaxoSmithKline), allowing their use for the prevention of major depressive episodes in adult patients with a history of seasonal affective disorder (SAD).According to a company news release, it is the first and only medication to be approved for this disorder, which affects approximately 6% of US adults.The approval was based on data from 3 placebo-controlled clinical trials in 1042 outpatients who were enrolled in the autumn prior to experiencing symptoms. Two of the studies were conducted during the 2002-2003 autumn-winter seasons and the third trial during the 2003-2004 season.Data from a Seasonal Pattern Assessment Questionnaire administered at baseline showed that although patients had experienced an average of 13 previous seasonal major depressive episodes, only 41% reported having received prior treatment for their chronic condition.Of these, 23% had received light therapy, and 76% had been given antidepressants. More than 50% of patients reported that their seasonal symptoms constituted a marked or severe problem, and 61% reported weight changes of 8 lbs or more that occurred primarily during autumn and winter months.For the study, patients were randomized to receive placebo or extended-release bupropion at a dose of 150 mg/day for the first week followed by uptitration to 300 mg/day as tolerated. Therapy was discontinued following a 2-week taper that began during early spring.Results of the 3 studies showed that the depression-free rate at the end of 4 to 6 months of therapy was higher in patients administered extended-release bupropion compared with placebo (81.4% vs 69.7%, 87.2% vs 78.7%, and 84.0% vs 69.0%, respectively; combined rates, 84.3% vs 72.0%).According to a company news release, the time-to-onset of a seasonal SAD episode also favored the extended-release bupropion group over placebo across the 3 studies, a difference that gained statistical significance during the 2003-2004 trial (P < .001).The tolerability of extended-release bupropion was consistent with that observed in previous trials for major depressive disorder. The most commonly reported adverse events occurring in greater than 5% of patients and at a rate exceeding 1.5 times that for placebo included dry mouth (26% vs 15%), nausea (13% vs 8%), constipation (9% vs 2%), and flatulence (6% vs 3%).The FDA notes that extended-release bupropion is indicated only for patients who meet strict diagnostic criteria for SAD episodes, including a seasonal pattern of recurrent, clinically significant depressive symptoms with associated impairment of functioning.Treatment of such individuals should generally be initiated in the autumn prior to the onset of depressive symptoms and continue through the winter season before being tapered and discontinued in early spring. The timing of initiation and duration of therapy should be individualized based on the patient's historical pattern of SAD episodes; those whose depressive episodes are infrequent or not associated with significant impairment are generally not eligible for prophylactic treatment.Therapy should be initiated with a 150-mg dose administered once daily in the morning and uptitrated to 300 mg/day (target dose) after 1 week if tolerated. For patients taking 300-mg/day extended-release bupropion during the autumn-winter season, the dose should be tapered to 150 mg/day for 2 weeks prior to discontinuation. The safety and efficacy of doses greater than 300 mg/day have not been evaluated for use in SAD prophylaxis.Bupropion extended-release tablets were approved previously for the treatment of major depressive disorder.

Higher-Dose Amlodipine Besylate/Benazepril HCl Capsules (Lotrel) for Managing Hypertension

On April 11, the FDA approved 5-mg/40-mg and 10-mg/40-mg amlodipine besylate/benazepril HCl capsules (Lotrel, made by Novartis Pharmaceuticals Corp) for use in the management of hypertension.The fixed-dose combination capsules were approved previously in 2.5-mg/10-mg, 5-mg/10-mg, 5-mg/20-mg, and 10-mg/20-mg strengths.According to a company news release, the higher-strength benazepril capsules are intended to expand dosing flexibility and offer new treatment options for patients who previously received no control and who may benefit from use of the highest available dose of the angiotensin-converting enzyme inhibitor benazepril. The new doses are expected to be available later this month.Amlodipine/benazepril capsules are indicated for use in those whose hypertension is not adequately controlled with either drug alone; they are not intended for first-line use.http://www.fda.gov/cder/whatsnew.htm

Learning Objectives for This Educational Activity

Upon completion of this activity, participants will be able to:

  • Evaluate the efficacy of bupropion extended-release tablets in the treatment of seasonal affective disorder.
  • Describe the appropriate use of extended-release bupropion for seasonal affective disorder.
  • Identify 2 new fixed-dose combinations for amlodipine/benazepril capsules in the treatment of uncontrolled hypertension.

Pearls for Practice

  • The FDA has approved bupropion extended-release tablets for the prevention of seasonal affective disorder in patients with a seasonal pattern of recurrent, clinically significant depressive symptoms with associated impairment of functioning. Combined results of 3 clinical trials showed that use of the drug was linked to an increased depression-free rate at the end of the winter season relative to placebo (84.3% vs 72.0%). Time to onset of a seasonal affective disorder episode also favored the treatment group over placebo and achieved statistical significance in 1 study.
  • Extended-release bupropion therapy for seasonal affective disorder should generally be initiated in the autumn prior to the onset of depressive symptoms with a single dose of 150 mg administered each morning. If tolerated, patients should be uptitrated to the target dose of 300 mg/day after 1 week. Therapy should continue through the winter season before being tapered to 150 mg/day for 2 weeks prior to discontinuation in early spring.
  • The FDA has approved 5-mg/40-mg and 10-mg/40-mg dosage strengths of amlodipine/benazepril capsules for the treatment of uncontrolled hypertension. The highest approved dose of the angiotensin-converting enzyme inhibitor benazepril is provided to improve dosing options and flexibility. The combination capsules are not intended for first-line use.

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

1. Read the target audience, learning objectives, and author disclosures. 2. Study the educational content online or printed out. 3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming. You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

Target Audience

This article is intended for primary care clinicians, psychiatrists, cardiologists, and other specialists who care for patients with seasonal affective disorder and uncontrolled hypertension.


The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.


Our Sponsors

Our Partners